Stira Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Stira Pharmaceuticals is a private, revenue-generating CDMO founded in 2020, headquartered in San Diego with operational facilities in Fairfield, New Jersey. The company's core business is providing analytical services and sterile injectable manufacturing for complex drug products across multiple therapeutic modalities. Its value proposition centers on technology-driven, partnership-focused support for pharmaceutical and biotech clients, offering capabilities from analytical R&D to fill-finish in batch sizes up to 2000L. Stira operates as a specialized service provider within the high-growth contract manufacturing sector for injectables.

Oncology

Technology Platform

Integrated CDMO service platform for sterile injectables, featuring comprehensive analytical testing (peptides, small molecules, oligonucleotides, biosimilars), formulation development, and automated robotic fill-finish manufacturing lines supporting vials, syringes, IV bags, and cartridges up to 2000L batch sizes.

Opportunities

The growing outsourcing trend in biopharma, coupled with the increasing complexity and number of injectable therapeutics (especially peptides, oligonucleotides, and biosimilars), creates a expanding market for specialized CDMOs.

Stira's U.S.-focus and end-to-end service model position it to capture demand from small and mid-sized biotechs lacking internal GMP capabilities.

Risk Factors

Key risks include high dependence on a limited client base, intense competition from larger CDMOs, and the significant operational/regulatory risks associated with sterile manufacturing where a single contamination event or FDA citation could severely damage reputation and operations.

Competitive Landscape

Stira competes in the crowded sterile injectable CDMO space against large global players (e.g., Catalent, Lonza, Thermo Fisher's Patheon) and numerous niche specialists. Differentiation is achieved through deep modality-specific analytical expertise, integrated services, and a partnership-focused approach, but scale and brand recognition of larger rivals pose a constant challenge.

More companies in Small Molecule Drugs →More companies in United States →